Total Payments
$17,809
2024 Payments
$2,829
Companies
33
Transactions
120
Medicare Patients
2,669
Medicare Billing
$180,991
Payment Breakdown by Category
Consulting$13,771 (77.3%)
Food & Beverage$3,121 (17.5%)
Education$745.30 (4.2%)
Travel$171.67 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,771 | 7 | 77.3% |
| Food and Beverage | $3,121 | 86 | 17.5% |
| Education | $745.30 | 25 | 4.2% |
| Travel and Lodging | $171.67 | 2 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,135 | 12 | $0 (2024) |
| Incyte Corporation | $4,802 | 8 | $0 (2020) |
| GENZYME CORPORATION | $2,162 | 3 | $0 (2022) |
| Janssen Biotech, Inc. | $1,652 | 5 | $0 (2024) |
| Karyopharm Therapeutics Inc. | $1,300 | 1 | $0 (2021) |
| Exelixis Inc. | $534.68 | 15 | $0 (2022) |
| PFIZER INC. | $330.86 | 21 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $255.48 | 7 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $186.26 | 7 | $0 (2024) |
| Genentech USA, Inc. | $164.99 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,829 | 47 | E.R. Squibb & Sons, L.L.C. ($1,800) |
| 2023 | $129.17 | 6 | AstraZeneca Pharmaceuticals LP ($36.46) |
| 2022 | $152.45 | 3 | GENZYME CORPORATION ($92.43) |
| 2021 | $2,857 | 20 | Karyopharm Therapeutics Inc. ($1,300) |
| 2020 | $4,442 | 4 | Incyte Corporation ($4,365) |
| 2019 | $637.96 | 11 | Incyte Corporation ($397.00) |
| 2018 | $502.82 | 9 | AstraZeneca Pharmaceuticals LP ($127.70) |
| 2017 | $6,259 | 20 | E.R. Squibb & Sons, L.L.C. ($2,161) |
All Payment Transactions
120 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Takeda Pharmaceuticals U.S.A., Inc. | VPRIV (Biological) | Food and Beverage | In-kind items and services | $33.39 | General |
| Category: GENETIC DISEASE | ||||||
| 12/17/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $25.84 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $1.31 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $26.85 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $25.79 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Immunology | ||||||
| 11/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $24.00 | General |
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $32.19 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.40 | General |
| Category: Hematology | ||||||
| 10/24/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: Oncology | ||||||
| 10/10/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $23.83 | General |
| Category: Oncology | ||||||
| 10/07/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $30.49 | General |
| 10/04/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $21.47 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $24.24 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Lilly USA, LLC | JAYPIRCA (Drug) | Food and Beverage | In-kind items and services | $25.80 | General |
| Category: Oncology | ||||||
| 08/27/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $21.19 | General |
| Category: Oncology | ||||||
| 08/20/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $23.38 | General |
| 08/12/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $20.36 | General |
| Category: Oncology | ||||||
| 07/18/2024 | PFIZER INC. | BOSULIF (Drug) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 723 | 1,329 | $241,470 | $55,834 |
| 2022 | 7 | 709 | 1,233 | $215,965 | $48,216 |
| 2021 | 8 | 647 | 1,129 | $201,861 | $45,396 |
| 2020 | 5 | 590 | 989 | $171,026 | $31,545 |
Total Patients
2,669
Total Services
4,680
Medicare Billing
$180,991
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 209 | 390 | $83,070 | $19,242 | 23.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 215 | 409 | $52,761 | $10,064 | 19.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 45 | 147 | $16,905 | $5,824 | 34.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 62 | 112 | $23,856 | $5,437 | 22.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 66 | $13,860 | $4,190 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 33 | 33 | $15,972 | $3,465 | 21.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 57 | 103 | $13,287 | $2,649 | 19.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 31 | 31 | $9,827 | $1,995 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 24 | $7,536 | $1,875 | 24.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 14 | 14 | $4,396 | $1,094 | 24.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 166 | 285 | $60,705 | $13,825 | 22.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 239 | 439 | $56,631 | $11,308 | 20.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 48 | 48 | $23,232 | $5,192 | 22.3% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 58 | 165 | $18,975 | $5,010 | 26.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 53 | 86 | $18,318 | $4,389 | 24.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 70 | 128 | $16,512 | $3,349 | 20.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 31 | 38 | $7,980 | $2,148 | 26.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 28 | 28 | $8,876 | $1,872 | 21.1% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 16 | 16 | $4,736 | $1,121 | 23.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 159 | 245 | $52,185 | $11,710 | 22.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 192 | 354 | $45,666 | $9,459 | 20.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 41 | 172 | $19,780 | $5,283 | 26.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 58 | 102 | $21,726 | $4,832 | 22.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 41 | 41 | $19,844 | $4,473 | 22.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 68 | 116 | $14,964 | $3,085 | 20.6% |
About Dr. Pradeep Jolly, MD
Dr. Pradeep Jolly, MD is a Hematology & Oncology healthcare provider based in Atlanta, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1023096823.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Pradeep Jolly, MD has received a total of $17,809 in payments from pharmaceutical and medical device companies, with $2,829 received in 2024. These payments were reported across 120 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($13,771).
As a Medicare-enrolled provider, Jolly has provided services to 2,669 Medicare beneficiaries, totaling 4,680 services with total Medicare billing of $180,991. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Atlanta, GA
- Active Since 01/03/2006
- Last Updated 04/21/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1023096823
Products in Payments
- OPDIVO (Biological) $3,335
- JEVTANA (Drug) $2,162
- DARZALEX (Biological) $1,531
- XPOVIO (Drug) $1,300
- Cabometyx (Drug) $205.08
- IMBRUVICA (Drug) $194.95
- LUTATHERA (Drug) $149.48
- TAGRISSO (Drug) $148.06
- IBRANCE (Drug) $140.60
- ADCETRIS (Biological) $125.00
- KEYTRUDA (Biological) $113.75
- Perjeta (Biological) $92.20
- ELREXFIO (Drug) $66.65
- KISQALI (Drug) $63.96
- VERZENIO (Drug) $59.77
- LYNPARZA (Drug) $57.65
- Padcev (Drug) $56.44
- NINLARO (Drug) $43.89
- REBLOZYL (Biological) $42.92
- TIVDAK (Biological) $42.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Atlanta
Dr. Jonathon Cohen, M.d, M.D
Hematology & Oncology — Payments: $330,523
Hematology & Oncology $330,523
Dr. Ajay Nooka, M.d., M.p.h.,F.a.c.p, M.D., M.P.H.,F.A.C.P
Hematology & Oncology — Payments: $256,358
Hematology & Oncology $256,358
Dr. Rodolfo Bordoni, Md, MD
Hematology & Oncology — Payments: $240,507
Hematology & Oncology $240,507
Dr. Mehmet Bilen, M.d, M.D
Hematology & Oncology — Payments: $134,196
Hematology & Oncology $134,196
Olatunji Alese, M.d, M.D
Hematology & Oncology — Payments: $131,083
Hematology & Oncology $131,083
Dr. Carlos Franco, Md, MD
Hematology & Oncology — Payments: $115,439
Hematology & Oncology $115,439